Form 4: Kura Oncology CLO Vests Shares, Sells for Tax

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, acquired shares through PSU vesting and subsequently sold a portion to cover tax obligations.

Summary

• Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, Inc., reported changes in her beneficial ownership of common stock.
• On November 13, 2025, Ms. Bair acquired 48,900 shares of common stock at a price of $0.00 per share, increasing her beneficial ownership to 196,943 shares.
• This acquisition resulted from the vesting of 1/6th of performance-based restricted stock units (PSUs) granted on May 31, 2023.
• The vesting was triggered by the achievement of one specified development milestone on November 13, 2025.
• On November 14, 2025, Ms. Bair disposed of 8,804 shares of common stock at a price of $11.1769 per share.
• This disposition was a 'sell-to-cover' transaction to satisfy tax obligations associated with the PSU vesting.
• Following the sale, Ms. Bair's direct beneficial ownership stands at 188,139 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The vesting of PSUs indicates the achievement of a development milestone, which is a positive operational sign for the company. The subsequent sale is a routine tax-related transaction and does not reflect a negative outlook on the company by the insider.

Positives

• The vesting of performance-based restricted stock units indicates that Kura Oncology has successfully met a specified development milestone, which is a positive operational achievement.

Negatives

• A portion of the vested shares was sold to cover tax liabilities, resulting in a reduction of the Chief Legal Officer's direct beneficial ownership.

Future Outlook

The remaining performance-based restricted stock units are contingent on the achievement of additional specified development milestones and the one-year anniversary of each milestone achievement, subject to continuous service.

Management Comments

• The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares of performance-based restricted stock units.

Industry Context

This is a routine insider transaction for a biotechnology company, reflecting the compensation structure for executives, where stock-based awards vest upon meeting specific performance criteria, such as development milestones. Sell-to-cover transactions for tax purposes are common practice following such vesting events.

Stakeholder Impact

• Shareholders: The achievement of a development milestone could be viewed positively, indicating progress in the company's pipeline. The insider sale is routine and unlikely to significantly impact sentiment.
• Employees: The vesting of PSUs reinforces the company's compensation structure tied to performance.

Next Steps

• Future vesting of the remaining performance-based restricted stock units will occur upon the achievement of other specified development milestones and the one-year anniversary of each milestone achievement, contingent on continuous service.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Transaction, Stock Vesting, PSU, Restricted Stock Units, Sell-to-Cover, Teresa Brophy Bair, Chief Legal Officer